Asahi Kasei Pharma

12:30 PM - 12:45 PM (PDT), Thursday, June 16, 2022 ・ Company Presentation Theater 2
Asahi Kasei Group contributes to life and living for people around the world by providing solutions to global challenges. In the healthcare business segment, we have two operating pharmaceuticals companies, Veloxis Pharmaceuticals, an U.S. based company and Asahi Kasei Pharma, a Japan based company. Our pharmaceutical business is positioned as a specialized, R&D-centered operation, with the development of new world class drugs being advanced to offer innovative and unique therapeutic solutions. We have a strong track record of partnering with small to large organizations, and successfully developed and commercialized a variety of innovative treatments with such partners. In BIO, we look for business development opportunities such as in-license, collaboration, investment, and M&A in the areas of transplant & its adjacent, immunology, and musculoskeletal disorders (incl. medical device). We also look for out-licensing opportunities of Recomodulin for CIPN and AK-1320 for spinal fusion.
Ticker:
3407
Exchange:
TYO
Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
AK1820
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2